Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
853.58B
Market cap853.58B
Price-Earnings ratio
39.43
Price-Earnings ratio39.43
Dividend yield
0.69%
Dividend yield0.69%
Average volume
2.84M
Average volume2.84M
High today
$920.00
High today$920.00
Low today
$898.15
Low today$898.15
Open price
$911.67
Open price$911.67
Volume
2.84M
Volume2.84M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 853.58B, Eli Lilly(LLY) trades at $903.31. The stock has a price-to-earnings ratio of 39.43 and currently yields dividends of 68.8%.

During the trading session on 2026-04-16, Eli Lilly(LLY) shares reached a daily high of $920.00 and a low of $898.15. At a current price of $903.31, the stock is +0.6% higher than the low and still -1.8% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 2.84M, versus its average volume of 2.84M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

The Wall Street Journal 9h
Eli Lilly Just Got Some Good News on Its Weight-Loss Pill

Eli Lilly just released results of a clinical trial that may ease concerns about the safety of its new weight-loss pill Foundayo, which seeks to rival a similar...

Eli Lilly Just Got Some Good News on Its Weight-Loss Pill
TipRanks 9h
Analysts Applaud as Eli Lilly’s Obesity Pill Is Found to Help Prevent Heart Attacks

The good news continues for pharmaceutical giant Eli Lilly (LLY) as its newly approved obesity pill has been found to help lower the risks of heart attacks. Cla...

Simply Wall St 9h
Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery

Eli Lilly (NYSE:LLY) has partnered with Vasa Therapeutics to use Vasa’s proprietary AI-enabled drug discovery platform. The collaboration focuses on accelerati...

Eli Lilly Expands TuneLab With Vasa AI Tie Up For Drug Discovery

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

Nasdaq 10h
Is This $6.3 Billion Deal a Game Changer for Eli Lilly?

Key Points It won't come cheap, as Eli Lilly is paying $6.3 billion in up-front payments in the deal. The pharmaceutical giant is also on the hook for up to $...

Is This $6.3 Billion Deal a Game Changer for Eli Lilly?
Benzinga 11h
Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar

The study showed that orforglipron met the primary goal of cardiovascular safety compared with insulin glargine in adults with type 2 diabetes and obesity or ov...

Eli Lilly's New Oral Weight Loss Drug Clears Cardiovascular Bar
The Wall Street Journal 12h
Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment

Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Mike Blake/Reuters Eli Lilly’s LLY -1...

Eli Lilly Reveals Results of Late-Stage Study for Type 2 Diabetes Treatment
Nasdaq 15h
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market

Key Points Eli Lilly has taken the lead over Novo Nordisk in the U.S. weight loss drug market. Both companies sell blockbusters and have recently released new...

Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
TipRanks 1d
Eli Lilly Stock Gets Another Buy Rating as Its Obesity Pill Hits the Market

BMO Capital Markets (BMO) is pounding the table on Eli Lilly’s (LLY) stock as the pharmaceutical giant launches its new weight-loss pill. Unlock hedge fund-lev...

The Motley Fool 1d
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

Three years ago, Eli Lilly (LLY 2.62%) and Novo Nordisk (NVO +2.21%) had about the same market value. Given how well both were performing, they were leading can...

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
TipRanks 1d
Eli Lilly asked for additional safety data on obesity pill, Reuters reports

The FDA has requested additional data from Eli Lilly (LLY) on potential liver injury linked to its newly approved obesity pill, along with post-marketing studie...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.